Further, the randomised SIPPET trial compared the inhibitor incidence in PwHA treated with recombinant vs plasma-derived FVIII concentrates and indicated a lower inhibitor risk when children were treated with plasma-derived products, however this did not reach statistical significance for high titre inhibitors. 6 Additionally, data from registries and cohorts are available and report partially discordant data.
← all excerpts
A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany - First Data from the GEPHARD Study Group.
1
—
—